| Name | Title | Contact Details |
|---|---|---|
Phyllis Balan |
VP, People and Culture | Profile |
Kleanthis Xanthopoulos |
Chairman and Chief Executive Officer | Profile |
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecules that are designed to modulate the fundamental immune responses underlying these diseases. RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4, including our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. The company is also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.
Volastra aims to extend the lives of patients with cancer by leveraging unique insights into chromosomal instability. Moving away from primary tumor models to target the site of metastasis in the toughest-to-treat solid tumors, we are altering the treatment paradigm for metastatic cancers.
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.
BD Biosciences - Canada is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Marligen Biosciences, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.